Troy Lister's most recent trade in Verve Therapeutics Inc was a trade of 7,340 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Verve Therapeutics Inc | Troy Lister | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 7,340 | 9,141 | - | - | Common Stock | |
| Verve Therapeutics Inc | Troy Lister | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 4,025 | 12,075 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Troy Lister | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 3,315 | 6,630 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Troy Lister | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 4.15 per share. | 01 Apr 2025 | 2,189 | 6,952 | - | 4.1 | 9,084 | Common Stock |
| Verve Therapeutics Inc | Troy Lister | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Verve Therapeutics Inc | Troy Lister | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2025 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Verve Therapeutics Inc | Troy Lister | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 32,000 | 32,000 | - | - | Stock Option (right to buy) |